Idiopathic Pulmonary Fibrosis (IPF): Update Bulletin [March 2016]

Idiopathic Pulmonary Fibrosis (IPF): Update Bulletin [March 2016]

Code: FW-21072016-09 | Published: Mar-2016 | Pages: 0 | FirstWord
Price :
$995.00
USD

* Required Fields

$995.00

Details

Gain new KOL insights on the latest events happening in idiopathic pulmonary fibrosis (IPF): Topics covered include opinions about Gilead’s suspension of a Phase II trial of simtuzumab; Boehringer Ingelheim’s initiation of a Phase IV trial combining Esbriet (pirfenidone) with Ofev (nintedanib), as well as views on DS Biopharma’s completion of a Phase I trial of an oral formulation of DS102 (15-HEPE).

How do KOLs view the recent failure of Gilead’s Phase II trial of simtuzumab?
Is simtuzumab’s mechanism of action worthy of further investigation for the treatment of IPF?
How do KOLs rate the importance of Boehringer Ingelheim’s Phase IV trial combining Esbriet with Ofev for the treatment of IPF?
How do KOLs view combining Esbriet with Ofev in terms of gastrointestinal tolerability and pharmacokinetics?
Will benefits in terms of efficacy and quality of life justify the high cost of combining Esbriet with Ofev?
How likely is it that the combination of Esbriet with Ofev will be used in preference to sequential therapy?
In light of recent data, what is the likelihood that an anti-inflammatory molecule, such as DS Biopharma’s DS102, will constitute a successful treatment approach for IPF?

Table of Contents

Report Format

Following are different modes of Licenses.

a. Single User License:
This license allows only one person to use the report. This person can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people. Unless you purchase a Site License or a Global Site License, a Single User License must be purchased for every single person that wishes to use the report within the same enterprise.

b. Single Site License:
This license allows unlimited users to use the report within one company location, e.g. a regional office. These users can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people.

c. Global Site License:
A Global Site License (or Enterprise wide Site License or Global License) is a license granted to original purchaser, who can share a report with other employees and authorized Users of the same organization.

Quick Help

1. How do you deliver the reports?
The delivery of reports is depends on format & mode of license of report(s). Following are different kinds of formats of report(s) and their delivery options :

a. Electronic Format – Through email from Publisher
Report will be sent to your username email address in PDF, Excel, PowerPoint or any other electronic / softcopy format by publisher.
Delivery Time: 12 to 48 hours [depending on time difference or occurrences of national holidays]

b. Hard Copy or Printed Format or CD-Rom – Through Mail or Courier from Publisher
Report will be sent through mail / courier delivery to your shipping address by publisher.
Delivery Time: Less than, few weeks [depending on time difference or occurrences of national holidays]


2. How can I make payment for publications I purchase?
You could be able to make the payment, in following ways:

a. Online Secure Payment through Credit Card Payment : We accept Visa, Master, AMEX Cards & CCAvenue
b. Transfer of fund to our bank account via Bank transfer or Wire transfer
c. Payment via DD or Cheque
d. Paypal


3. Is it safe to use my credit card on MarketinfoResearch?
Your personal information and online tranaction on Marketinfo Research is secure, private, and tamper-proof. All credit card payments are processed through secure and trusted payment gateways.

If you have a more question about our publications please see our FAQs section or contact us now at cs@marketinforesearch.com.

Browse similar reports by category:
Pharmaceuticals & Healthcare
FirstWord

Our Clients